Applications of pharmacokinetic/pharmacodynamic research in rational drug development

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 18, Issue SUPPL. C, 1996, Pages 53-54

  Danhof, M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; FENTANYL; NIFEDIPINE; REMIFENTANIL; SUFENTANIL;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG DEVELOPMENT; DRUG RESEARCH; HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS;

ANESTHETICS, INTRAVENOUS; DRUG DESIGN; DRUG EVALUATION; HUMANS; PHARMACOKINETICS; PHARMACOLOGY; PIPERIDINES; RESEARCH;

EID: 0029749999     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Danhof, M., Mandema, J.W. Modelling of relationships between pharmacokinetics and pharmacodynamics. In: Pharmacokinetics-Regulatory, Industrial and Academic Perspectives. Welling, P.O., Tse, F.L. (Eds.). Marcel Dekker: New York 1995, 139-174.
2. Breimer, D.D., Danhof, M. Relevance of the application of PK/PD modelling concepts in drug development: The wooden shoe paradigm. Clin Pharmacokin, in press.
3. Danhof, M., Mandema, J.W., Hoogerkamp, A., Mathôt, R.A.A. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: Principles and perspectives. Europ J Drug Metab Pharmacokin 1993, 18: 41-47.
4. Levy, G. The case for pre-clinical pharamcodynamics. In: Integration of Pharmacokinetics, Pharmacodynamics and Toxicokinetics in rational Drug Development. Yacobi, A., Skelly, J.P., Shah, V.P., Benet, L.Z. (Eds.). Plenum Press: New York 1993, 7-13.
5. Collins, J.M. Use of pharmacokinetics and pharamcodynamics in preclinical studies to guide dose escalation schemes in phase 1 studies of anticancer drugs. In: Integration of Pharmacokinetics, Pharmacodynamics and Toxicokinetics in Rational Drug Development. Yacobi, A., Skelly, J.P., Shah, V.P., Benet, L.Z. (Eds.). Plenum Press: New York 1993, 49-54.
6. Yacobi, A., Wingard, L.B., Levy, G. Comparative pharmacokinetics of coumarin anticoagulants X: Relationship between distribution, elimination and anticoagulant action of warfarin. J Pharm Sci 1974, 63: 868-872.
7. Nagashima, R., O'Reilly, R., Levy, G. Kinetics of pharmacologic effect in man: The anticoagulant action of warfarin. Clin Pharmacol Ther 1969, 10: 22-35.
8. Mandema, J.W., Tukker, E., Danhof, M. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: Midazolam and flumazenil. J Pharmacol Exp Ther 1992, 260: 36-44.
9. Breimer, L.T.M., Burm, A.G.L., Danhof, M., Hennis, P.J., Vletter, A.A., de Voogt, J.W.H., Spierdijk, J., Bovill, J.G. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. Clin Pharmacokinet 1991, 20: 497-508.
10. Egan, T.D., Lemmens, H.J.M., Fiset, P., Muir, K.T., Hermann, D.J., Stanski, D.R. The pharmacokinetics and pharmacodynamics of remifentanil. Anesthesiology 1992, A369.
11. Kleinbloesem, c.H., Van Brummelen, P., Van Harten, J., Danhof, M., Breimer, D.D. Nifedipine: Influence of renal function on pharmacokinetic/haemodynamic relationship. Clin Pharmacol Ther 1985, 37: 563-574.
12. Kleinbloesem, C.H., Van Harten, J., Wilson, J.H.P., Danhof, M., Van Brummelen, P., Breimer, D.D. Nifedipine: Kinetics and dynamics in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 1986, 40: 21-28.